期刊
INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 -, 期 -, 页码 -出版社
SPRINGER JAPAN KK
DOI: 10.1007/s12185-023-03653-4
关键词
Multiple myeloma; Proteosome inhibitors; Immunomodulatory drugs
类别
This study retrospectively analyzed data on the clinical outcomes and management of novel drug-containing therapies for newly diagnosed multiple myeloma (MM) patients. The results showed that these regimens demonstrated durable responses and manageable adverse events (AEs) in the real-world setting. However, certain poor prognostic factors were identified, such as poor performance status.
To investigate the real-world clinical outcomes and management of novel drug-containing therapies for newly diagnosed multiple myeloma (MM) patients, we retrospectively analyzed data on the first-line treatment for newly diagnosed transplant-ineligible MM patients from Kansai Myeloma Forum, a registry network in Japan. A total of 598 patients treated with novel drugs between March 2007 and February 2018 were analyzed. Regimens used were VD (n = 305), Rd (n = 103), VMP (n = 97), VCD (n = 71), and VRd (n = 22). Younger patients tended to receive VRd or VCD, whereas the regimen with the highest median patient age was Rd. More than three-quarters of patients in the Rd group received a reduced dose of lenalidomide. The Rd and VRd groups had a relatively high incidence of infection and skin complications, and the VMP group had the highest incidence of peripheral neuropathy. Overall response rate did not differ significantly between regimens. Multivariate analysis in all patients revealed several poor prognostic factors, such as poor performance status. Novel drug-containing regimens for newly diagnosed MM showed a durable response with manageable AEs in the real-world setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据